chloroethylaminouracil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

chloroethylaminouracil: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	68216
SCHEMBL ID	2504789
MeSH ID	M0049876

Synonyms (42)

Synonym
AKOS003398887
nsc-446297
wln: t6mvmvj en2g2g f1
4-methyl-5-[bis(.beta.-chloroethyl)amino]uracil
dopane
2,6-dihydroxy-4-methyl-5-bis(2-chloroethyl)aminopyrimidine
dopan
ent 50698
520-09-2
nsc44629
nsc-44629
uracil, 5-[bis(2-chloroethyl)amino]-6-methyl-
chloroethylaminouracil
5-[bis(2-chloroethyl)amino]-6-methyluracil
2,3h)-pyrimidinedione, 5-[bis(2-chloroethyl)amino]-6-methyl-
6-methyl-5-[bis(2-chloroethyl)amino]uracil
elderfield pyrimidine mustard
nsc-23436
2,4(1h,3h)-pyrimidinedione, 5-(bis(2-chloroethyl)amino)-6-methyl-
5-(bis(2-chloroethyl)amino)-6-methyluracil
ai3-50698
uracil, 5-(bis-(2-chloroethyl)amino)-6-methyl-
4-methyl-5-(bis(beta-chloroethyl)amino)uracil
5-(bis-(2-cloroetil)-amino)-6-metiluracile [italian]
nsc 44629
6-methyl-5-(bis(2-chloroethyl)amino)uracil
uracil, 5-(bis(2-chloroethyl)amino)-6-methyl- (van)
5-[bis(2-chloroethyl)amino]-6-methyl-1h-pyrimidine-2,4-dione
2,6-dihydroxy-4-methyl-5-[bis(2-chloroethyl)amino]pyrimidine
unii-1ly7uh1wut
1ly7uh1wut ,
5-(bis-(2-cloroetil)-amino)-6-metiluracile
5-(bis(2-chloroethyl)amino)-6-methyl-2,4(1h,3h)-pyrimidinedione
uracil, 5-(bis(2-chloroethyl)amino)-6-methyl-
dopan [mi]
SCHEMBL2504789
DTXSID50199958
5-[bis(2-chloroethyl)amino]-6-methylpyrimidine-2,4(1h,3h)-dione
FT-0707623
5-(bis(2-chloroethyl)amino)-6-methylpyrimidine-2,4(1h,3h)-dione
Q27252592
SB59675

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	22 (88.00)	18.7374
1990's	1 (4.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	2 (8.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.80

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	10.80 (24.57)
Research Supply Index	3.47 (2.92)
Research Growth Index	4.26 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (10.80)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (3.33%)	5.53%
Reviews	1 (3.33%)	6.00%
Case Studies	1 (3.33%)	4.05%
Observational	0 (0.00%)	0.25%
Other	27 (90.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
uracil 2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder	3.73	11	pyrimidine nucleobase; pyrimidone	allergen; Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; prodrug; Saccharomyces cerevisiae metabolite
beta-aminoethyl isothiourea beta-Aminoethyl Isothiourea: A radiation-protective agent that can inhibit DNA damage by binding to the DNA. It also increases the susceptibility of blood cells to complement-mediated lysis.	1.93	1
busulfan [no description available]	1.93	1	methanesulfonate ester	alkylating agent; antineoplastic agent; carcinogenic agent; insect sterilant; teratogenic agent
chlorpromazine Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.	1.93	1	organochlorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug
mechlorethamine nitrogen mustard : Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.	3.32	7	nitrogen mustard; organochlorine compound	alkylating agent
procarbazine Procarbazine: An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.. procarbazine : A benzamide obtained by formal condensation of the carboxy group of 4-[(2-methylhydrazino)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.	1.95	1	benzamides; hydrazines	antineoplastic agent
prednisolone Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.. prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.	1.95	1	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; drug metabolite; environmental contaminant; immunosuppressive agent; xenobiotic
phenylalanine Phenylalanine: An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE.. L-phenylalanine : The L-enantiomer of phenylalanine.. phenylalanine : An aromatic amino acid that is alanine in which one of the methyl hydrogens is substituted by a phenyl group.	1.93	1	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; phenylalanine; proteinogenic amino acid	algal metabolite; EC 3.1.3.1 (alkaline phosphatase) inhibitor; Escherichia coli metabolite; human xenobiotic metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
uracil mustard Uracil Mustard: Nitrogen mustard derivative of URACIL. It is a alkylating antineoplastic agent that is used in lymphatic malignancies, and causes mainly gastrointestinal and bone marrow damage.	4.42	23	aminouracil; nitrogen mustard
rotenone Derris: A plant genus of the family FABACEAE. The root is a source of rotenoids (ROTENONE) and flavonoids. Some species of Pongamia have been reclassified to this genus and some to MILLETTIA. Some species of Deguelia have been reclassified to this genus.. rotenoid : Members of the class of tetrahydrochromenochromene that consists of a cis-fused tetrahydrochromeno[3,4-b]chromene skeleton and its substituted derivatives. The term was originally restricted to natural products, but is now also used to describe semi-synthetic and fully synthetic compounds.	2.41	1	organic heteropentacyclic compound; rotenones	antineoplastic agent; metabolite; mitochondrial NADH:ubiquinone reductase inhibitor; phytogenic insecticide; piscicide; toxin
quinacrine mustard Quinacrine Mustard: Nitrogen mustard analog of quinacrine used primarily as a stain in the studies of chromosomes and chromatin. Fluoresces by reaction with nucleic acids in chromosomes.	1.97	1	hydrochloride	intercalator
isothiuronium Isothiuronium: An undecenyl THIOUREA which may have topical anti-inflammatory activity.	1.93	1
melphalan Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.	2.86	4	L-phenylalanine derivative; nitrogen mustard; non-proteinogenic L-alpha-amino acid; organochlorine compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
mannomustine Mannomustine: Nitrogen mustard derivative alkylating agent used as antineoplastic. It causes severe bone marrow depression and is a powerful vesicant.	2.63	3	amino alcohol
bilirubin [no description available]	4	2	biladienes; dicarboxylic acid	antioxidant; human metabolite; mouse metabolite
nitrophenols Nitrophenols: PHENOLS carrying nitro group substituents.	1.93	1

Condition	Relationship Strength	Studies
Nerve Degeneration Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.	4.02	9
Idiopathic Parkinson Disease [description not available]	5.05	10
Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)	5.05	10
Innate Inflammatory Response [description not available]	3.52	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	3.52	1
Benign Neoplasms [description not available]	2.63	3
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.63	3
Leucocythaemia [description not available]	2.85	4
Granulocytic Leukemia [description not available]	2.34	2
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	2.85	4
Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.	2.34	2
Experimental Neoplasms [description not available]	1.93	1
Leukocytopenia [description not available]	2.34	2
Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).	2.34	2
Granuloma, Hodgkin [description not available]	3.44	8
Leukocyte Disorders Disordered formation of various types of leukocytes or an abnormal accumulation or deficiency of these cells.	1.94	1
Thrombopenia [description not available]	1.94	1
Hodgkin Disease A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.	3.44	8
Thrombocytopenia A subnormal level of BLOOD PLATELETS.	1.94	1
Besnier-Boeck Disease [description not available]	2.34	2
Sarcoidosis An idiopathic systemic inflammatory granulomatous disorder comprised of epithelioid and multinucleated giant cells with little necrosis. It usually invades the lungs with fibrosis and may also involve lymph nodes, skin, liver, spleen, eyes, phalangeal bones, and parotid glands.	2.34	2
Poisoning Used with drugs, chemicals, and industrial materials for human or animal poisoning, acute or chronic, whether the poisoning is accidental, occupational, suicidal, by medication error, or by environmental exposure.	2.35	2
Blood Diseases [description not available]	1.93	1
Leukemia, Lymphocytic [description not available]	1.93	1
B-Cell Chronic Lymphocytic Leukemia [description not available]	1.93	1
Hematologic Diseases Disorders of the blood and blood forming tissues.	1.93	1
Leukemia, Lymphoid Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts.	1.93	1
Leukemia, Lymphocytic, Chronic, B-Cell A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.	1.93	1
Acute Disease Disease having a short and relatively severe course.	1.95	1
Leukemia L 1210 [description not available]	1.97	1

chemdatabank.com